Raymond James Upgrades HealthEquity (NASDAQ:HQY) to “Strong-Buy”

Raymond James upgraded shares of HealthEquity (NASDAQ:HQY) from an outperform rating to a strong-buy rating in a report released on Tuesday, MarketBeat reports. Raymond James currently has $115.00 target price on the stock, down from their prior target price of $120.00.

Several other equities analysts have also recently commented on the stock. Barrington Research reissued an “outperform” rating and set a $112.00 target price on shares of HealthEquity in a research note on Friday, March 14th. JMP Securities raised their price objective on shares of HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 10th. KeyCorp reduced their target price on shares of HealthEquity from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Monday. Royal Bank of Canada boosted their price target on shares of HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, Wells Fargo & Company lifted their price target on HealthEquity from $110.00 to $125.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, HealthEquity has an average rating of “Buy” and a consensus target price of $112.23.

HealthEquity Trading Down 0.4 %

NASDAQ:HQY opened at $88.83 on Tuesday. HealthEquity has a 1 year low of $65.01 and a 1 year high of $115.59. The business has a fifty day moving average of $103.94 and a 200-day moving average of $95.84. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. The stock has a market cap of $7.68 billion, a price-to-earnings ratio of 81.50, a PEG ratio of 1.60 and a beta of 0.62.

Insider Buying and Selling

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $111.29, for a total value of $639,917.50. Following the completion of the sale, the director now owns 78,219 shares of the company’s stock, valued at $8,704,992.51. The trade was a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI acquired a new position in HealthEquity during the fourth quarter valued at approximately $26,000. Transce3nd LLC bought a new stake in shares of HealthEquity during the 4th quarter worth $29,000. Smartleaf Asset Management LLC grew its stake in HealthEquity by 34.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company’s stock valued at $37,000 after buying an additional 98 shares during the last quarter. Proficio Capital Partners LLC bought a new position in HealthEquity in the 4th quarter worth $39,000. Finally, UMB Bank n.a. lifted its position in HealthEquity by 65.6% during the 4th quarter. UMB Bank n.a. now owns 414 shares of the company’s stock worth $40,000 after acquiring an additional 164 shares during the last quarter. 99.55% of the stock is owned by institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.